OBJECTIVE
To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.
METHODS
Open label, randomised, parallel group, phase II study.
METHODS
Five UK